Nanohale AG (FYB) | Finanzwire

Basculer en Français

8295	Companies
114833	Keywords
55274	Articles
62430	Press releases

Home
Companies
Nanohale AG

BRIEF

published on 11/19/2024 at 06:35, 2 days 4 hours ago

Formycon Announces Earnings Call and Conference Participation

Financial Results Investor Conference Frankfurt Stock Exchange Formycon AG Earnings Call
PRESS RELEASE

published on 11/19/2024 at 06:30, 2 days 4 hours ago

Formycon invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences
Formycon AG invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences. Management Board to discuss key financial figures and recent uplisting to the Prime Standard of Frankfurt Stock Exchange

Investor Conferences Formycon AG Biosimilars Earnings Call Nine-month Results
BRIEF

published on 11/18/2024 at 06:35, 3 days 4 hours ago

Formycon's FYB203 Biosimilar Receives Positive CHMP Opinion

Formycon AG Biosimilar FYB203 CHMP Approval Aflibercept
PRESS RELEASE

published on 11/18/2024 at 06:30, 3 days 4 hours ago

Formycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama®
Formycon receives positive CHMP opinion for FYB203, a biosimilar candidate to Eylea, under tradenames AHZANTIVE and Baiama. Approval decision by European Commission expected in January 2025

Formycon Eylea CHMP Opinion Biosimilar Candidate AHZANTIVE
BRIEF

published on 11/15/2024 at 18:23, 5 days 16 hours ago

Positive CHMP Opinion for Formycon's Aflibercept-Biosimilar FYB203

Formycon AG FYB203 CHMP Opinion EMA Approval Biosimilar Drug
PRESS RELEASE

published on 11/15/2024 at 18:18, 5 days 16 hours ago

EQS-Adhoc: Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA
Formycon AG announces positive CHMP opinion from EMA for Aflibercept-Biosimilar FYB203 (AHZANTIVE®/ Baiama®) as a treatment for retinal diseases. Market approval expected by January 2025

Formycon AG EMA Retinal Diseases CHMP Opinion Aflibercept-Biosimilar FYB203
BRIEF

published on 11/11/2024 at 17:46, 9 days 16 hours ago

Formycon AG Extends CEO Contract and Joins Prime Standard

Frankfurt Stock Exchange Formycon AG Biosimilars Prime Standard Stefan Glombitza
PRESS RELEASE

published on 11/11/2024 at 17:41, 9 days 17 hours ago

Formycon extends Management Board contract for CEO Dr. Stefan Glombitza until 2027 and receives admission to trading in the Prime Standard
Formycon extends CEO contract until 2027. Receives admission to trading in Frankfurt Stock Exchange's Prime Standard. Company's biosimilars contribute to healthcare accessibility and cost reduction

Frankfurt Stock Exchange Biosimilars Formycon Prime Standard CEO Contract
BRIEF

published on 11/04/2024 at 06:35, 17 days 4 hours ago

Formycon Seeks Prime Standard Listing on Frankfurt Stock Exchange

Frankfurt Stock Exchange Formycon AG Biosimilars Prime Standard Investor Appeal
PRESS RELEASE

published on 11/04/2024 at 06:30, 17 days 4 hours ago

Formycon applies for admission to the Prime Standard of the Frankfurt Stock Exchange
Formycon AG applies for admission to the Prime Standard of the Frankfurt Stock Exchange to enhance international visibility and investor base

Frankfurt Stock Exchange Formycon AG Uplisting Admission Prime Standard

Accesswire

Published on 11/21/2024 at 10:03, 41 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 44 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 44 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours 9 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 19 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 10:30, 14 minutes ago

MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024
Published on 11/21/2024 at 10:04, 39 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 42 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 44 minutes ago

Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 44 minutes ago

Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV

Les Echos

Published on 11/21/2024 at 06:58, 3 hours 46 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 24 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 16 hours 59 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 16 hours 59 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 2 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE